Genedata Profiler strengthens our innovative potential to ultimately allow us to bridge the gap between research and real-world application by consolidating large amounts of diverse, multi-source data and making it easy for our teams to use.
BASEL, Switzerland (PRWEB)
May 25, 2023
Genedata, a leading enterprise software provider for biopharmaceutical R&D, has announced that global biopharmaceutical company Debiopharm will adopt its Genedata Profiler as a single point of access to translational research data, accelerating R&D activities and speeding up the development of life-saving drugs for underserved patients. “With Genedata Profiler, we have found a digital solution to maximize the value of our R&D data to advance our drug development programs,” said Carolina Haefliger, Head of Translational Medicine at Debiopharm.
Debiopharm, which aims to develop innovative therapies targeting high unmet medical needs in oncology and bacterial infections, will use Genedata Profiler to support its mission of translating scientific findings into effective therapeutic products and enhancing clinical trial success rates through data-driven decisions. The platform provides Debiopharm with:
- A single point of access to internal and external data sources, including public databases and CROs, to improve data discoverability and usability;
- Automated pipelines for high-performance data processing, harmonization, and integration, enabling analysts to transform unstructured high-dimensional multi-modal data into interoperable, analysis-ready data products for comparable cross-study analyses; and
- An extendable visualization and statistical toolbox for intuitive and self-service data investigation and hypothesis testing.
By centralizing dispersed data, democratizing access to analytical tools, and digitizing and automating data operations, Genedata Profiler strengthens Debiopharm’s ability to seamlessly explore, analyze, and interpret data, streamlining insight generation. The platform is also expected to encourage R&D innovation and productivity by enabling improved data ownership and usability.
In addition to the Genedata Profiler, Debiopharm will benefit from consulting services, which will ensure seamless implementation of the software within its IT infrastructure, efficient platform operation for increased ROI, and company-specific custom developments such as fit-for-purpose data visualizations. “The adoption of Genedata Profiler as a single point of truth will help Debiopharm boost their innovative R&D engines, ultimately bringing much-needed precision medicines faster to patients,” said Othmar Pfannes, CEO of Genedata.
For more information on Debiopharm please visit http://www.debiopharm.com, and for more information on Genedata, visit http://www.genedata.com.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Share article on social media or email: